Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer’s 14th World Conference on Lung Cancer , July 3-7 in Amsterdam, The Netherlands.
“While lung cancer remains a difficult-to-treat disease, we’re learning more about how therapies like crizotinib and PF-299 may be able to specifically target ALK or the HER pathway, respectively, and how this may lead to more rationally selected and personalized therapy,” said Maurizio Voi, MD, Thoracic Tumor Strategy Lead, Pfizer Oncology. “Data being presented show survival outcomes for PF-299 and crizotinib, as well as quality-of-life or patient-reported outcomes after treatment for patients with non small cell lung cancer, which represent important considerations in determining the best treatment option for these patients.”
First Presentation of PF-299 Preliminary Overall Survival Data
Pfizer will present, for the first time, preliminary overall survival data from a Phase 2 study evaluating PF-299 vs erlotinib in patients with advanced non-small cell lung cancer after progression on at least one chemotherapy regimen .
Pfizer also will present patient-reported outcomes from clinical trials of PF-299 in refractory and second-/third-line NSCLC, which provide a better understanding of the patient’s perspective of the burden of adverse events associated with treatment and how it may change over time.
- Gastrointestinal toxicity of the pan-HER tyrosine kinase inhibitor PF299804: Assessment by patient-reported outcomes in second-/third-line and refractory NSCLC
- Dermatologic adverse events of the pan-HER tyrosine kinase inhibitor PF299804: Assessment by patient-reported outcomes in second-/third-line and refractory NSCLC
Based on results from across the PF-299 clinical trial program, Pfizer has initiated a Phase 3 trial, ARCHER 1009, evaluating PF-299 vs erlotinib for the treatment of patients with locally advanced or metastatic NSCLC following progression after, or intolerance to, at least one prior chemotherapy. ARCHER 1009 will assess the efficacy and safety of PF-299 in two co-primary populations: all enrolled patients, and enrolled patients with KRAS wild type status. The ARCHER 1009 study is open for enrollment in the US and will be enrolling soon in other countries.
Similar Posts:
- Review of lung cancer from non-smoker patient to be revealed at IASLC conference
- Arno AR-67 Phase II clinical study for glioblastoma meets pre-defined interim goals
- For chronic fatigue sufferers, another blow
- Going to the hospital this month? Beware the ‘July effect.’
- For crow’s feet, new drug is better than Botox
